Lakshmi Basavegowda

Lakshmi Basavegowda

Auto-generated profile, based on publicly available information

Lakshmi Basavegowda

Department of Chemistry, School of Applied Science, REVA University, Bangalore-560064, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2025 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
RKRushendra Reddy Kothinti
Rushendra Reddy Kothinti
LBLakshmi Basavegowda
Lakshmi Basavegowda
SBSrinu Bhoomandla
Srinu Bhoomandla
NGNageswara Reddy Gosu
Nageswara Reddy Gosu
SMSudha Muppavarapu
Sudha Muppavarapu
MRMohammad Raish
Mohammad Raish

20 February 2026 in RSC Advances
Verified
Journal Article
Open access
PDF file
SMSubhash Rao Marata
Subhash Rao Marata
Tushar Janardan PawarTushar Janardan Pawar
Tushar Janardan Pawar
JOJosé Luis Olivares-Romero
José Luis Olivares-Romero
HPHarun Patel
Harun Patel
IAIqrar Ahmad
Iqrar Ahmad
LBLakshmi Basavegowda
Lakshmi Basavegowda
The emergence of multidrug-resistant (MDR) pathogens has intensified the need for novel antimicrobial agents. This study focuses on the design, synthesis, and evaluation of hybrid peptides (6a–6e) incorporating unnatural amino acids featuring enhanced hydrophobic side chains. These peptides, particularly 6e, demonstrated potent antimicrobial efficacy. Molecular docking identified the robust binding affinities of peptides 6e and 6b towards the transglycosylase domain of Escherichia coli PBP1b, indicating their potential as enzyme inhibitors. Molecular dynamics (MD) simulations confirmed the stability of peptide-protein complexes over a 100 ns timespan, supporting the structural integrity of peptide 6e. Experimental data further validated computational predictions, with peptide 6e exhibiting minimum inhibitory concentrations (MICs) as low as 2 µg mL−1 against E. coli and 0.2 µg mL−1 against Bacillus subtilis. Additionally, 6e demonstrated broad-spectrum antifungal efficacy, showing competitive activity against Candida albicans and Aspergillus niger. These results establish unnatural amino acid-based peptides as promising candidates in addressing MDR infections, warranting further studies for clinical application.

30 December 2024 in Organic Communications
Verified
Journal Article
Closed access
LBLakshmi Basavegowda
Lakshmi Basavegowda
AMAiyagala M.M. Mallikarjunasawamy
Aiyagala M.M. Mallikarjunasawamy
KGKuruvalli Gouthami
Kuruvalli Gouthami
SMSubhasish Maity
Subhasish Maity
DVDamodara Reddy Vaddi
Damodara Reddy Vaddi
Cancer has been a widespread disease for decades in various of types for decades, and the search for effective treatments continues. Researchers are exploring various new drugs, including natural compounds and small organic molecules, for their potential to combat cancer. One promising approach involves hybrid structures that combine different pharmacophore units with known biological activities. These structures have gained popularity due to their encouraging results. In this study, we synthesized several new hybrid compounds containing 1,2,3-triazole units. We confirmed the structures of these compounds using methods like ¹H NMR, ¹³C NMR, and LC-MS. We then evaluated their antioxidant properties and in vitro anticancer activities. The results showed that these new compounds demonstrated having good radical scavenging activity and potential agents for anticancer activity. Notably, compounds 3b, 3d, 3a, 3m, and 3i exhibited low concentrations of IC50 values (14.08±0.6, 14.3±0.8, 15.82±0.4, 18.12±0.86 and 19.7±0.88 μg/mL, respectively) when compared to the standard drug Cisplatin (IC50: 21.13±1.6 µg/mL). Computational analysis has been performed like ADMET evaluation and Molecular docking studies revealed the compounds having good binding affinity with cancer target proteins like HIF-1α ranging from -8.1 kcal/mol to -7.0 kcal/mol and HER2 ranging from -10.0 kcal/mol to -8.8 kcal/mol respectively when compared with standard drug Cisplatin showed binding affinity ranging from -4.2 kcal/mol to -3.9 kcal/mol.